Ovarian Cancer Clinical Trial
Official title:
Early Detection of Epithelial Ovarian Cancer Using Exhaled Breath Markers: GC/FT-ICR Mass Spectrometry and Canine Olfaction.
RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer,
polycystic ovarian syndrome, or endometriosis and from healthy participants in the
laboratory may help doctors identify and learn more about biomarkers related to cancer. It
may also help doctors find and diagnose ovarian epithelial cancer sooner, when it may be
easier to treat.
PURPOSE: This clinical trial is studying exhaled breath biomarkers to see how well they find
ovarian epithelial cancer in patients with newly diagnosed ovarian epithelial cancer,
polycystic ovarian syndrome, or endometriosis and in healthy participants.
OBJECTIVES:
- Identify patterns of exhaled compounds in breath samples from patients with newly
diagnosed ovarian epithelial cancer that are significantly and reproducibility
different from those of healthy volunteers using gas chromatography Fourier transform
ion cyclotron resonance mass spectrometry (GC/FT-ICR MS).
- Train five canines to discriminate between exhaled breath samples from patients with
newly diagnosed ovarian epithelial cancer and healthy volunteers.
- Use both canine olfaction and GC/FT-ICR MS to distinguish between exhaled breath
samples from patients with newly diagnosed ovarian epithelial cancer and patients with
polycystic ovarian syndrome or endometriosis.
- Repeat breath sampling in patients with newly diagnosed ovarian epithelial cancer
throughout the course of diagnosis and therapy.
OUTLINE: Exhaled breath samples are collected from patients and healthy volunteers. The
samples are analyzed by gas chromatography Fourier transform ion cyclotron resonance mass
spectrometry (GC/FT-ICR MS) to determine chemical compositions, identities, and predictive
patterns of biomarkers in exhaled breath condensate. GC/FT-ICR MS and trained canine
olfaction are used to distinguish between exhaled breath samples from patients with ovarian
epithelial cancer, patients with polycystic ovarian syndrome or endometriosis, and healthy
volunteers.
Patients and healthy volunteers complete questionnaires about BRCA 1 and BRCA 2 status (if
known), alcohol use, smoking (including duration and type of cigarettes), physical activity
(duration and type), socioeconomic status, education, county of residence, age at menopause
(if applicable), age at menarche, presence of first- and second-degree family history of
breast cancer or ovarian epithelial cancer, body mass index (height and weight), and
co-morbidities.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |